Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About Us
    • AACR Journals
    • Subscriptions
    • Permissions & Reprints
    • Advertising
  • Article Collections
    • Focus Sections
    • Journal Collections
    • Hot Topics
    • "Best of" Collection
    • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Researchers Behind the Journals: Researcher Profiles
  • Alerts
    • Table of Contents
    • Editors' Picks
  • COVID-19
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Log in
  • My Cart

Search

  • Advanced search
American Association for Cancer Research

American Association for Cancer Research

Advanced Search

  • Home
  • About Us
    • AACR Journals
    • Subscriptions
    • Permissions & Reprints
    • Advertising
  • Article Collections
    • Focus Sections
    • Journal Collections
    • Hot Topics
    • "Best of" Collection
    • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Researchers Behind the Journals: Researcher Profiles
  • Alerts
    • Table of Contents
    • Editors' Picks
  • COVID-19
  • Visit AACR on Facebook
  • Follow AACR on Twitter
  • Visit AACR on LinkedIn
  • Visit AACR on YouTube

Clonal Trajectories and Cellular Mechanisms of Relapse in ALL

«  back to webinars page

Get Webinar Alerts

To receive notifications about upcoming and recorded webinars, sign up for alerts.

* indicates required

 

 

 

Journal Club:
Cancer Discovery & Blood Cancer Discovery with Dr. Charles G. Mullighan and Dr. John E. Dick

Moderated by: Tanya Bondar, PhD, Blood Cancer DiscoveryDeputy Editor
Recorded: 7/15/2020

Watch the recording of the AACR Virtual Journal Club: Cancer Discovery & Blood Cancer Discovery session, featuring John E. Dick, PhD, FRS of the University of Toronto and Charles G. Mullighan, MBBS (hons), MSc, MD of St. Jude Children’s Hospital, as they present their findings, published back-to-back, in Cancer Discovery & Blood Cancer Discovery: "Relapse-Fated Latent Diagnosis Subclones in Acute B Lineage Leukemia Are Drug Tolerant and Possess Distinct Metabolic Programs" and "Mutational Landscape and Patterns of Clonal Evolution in Relapsed Pediatric Acute Lymphoblastic Leukemia.”

Isolation and characterization of subclones from diagnosis samples of patients with B-ALL who relapsed showed that relapse-fated subclones had increased drug tolerance and distinct metabolic and survival transcriptional programs compared with other diagnosis subclones. Dr. John E. Dick’s study provides strategies to identify and target clinically relevant subclones before further evolution toward relapse.

Dr. Charles G. Mullighan’s study defines the landscape of mutations that preexist and arise after commencement of ALL therapy and shows that relapse may be propagated from ancestral, major, or minor clones at initial diagnosis. A subset of cases exhibit hypermutation that results in expression of neoepitopes that may be substrates for immunotherapeutic intervention.

Stay tuned for the Q&A session at the end of the recording.

 

About the Featured Speakers:

Charles G. Mullighan, MBBS (Hons), MSc, MD is the Deputy Director of the St. Jude Children’s Research Hospital Comprehensive Cancer Center and Co-Leader of the Cancer Center’s Hematological Malignancies Program. His research focuses on defining the landscape of genomic and epigenomic alterations that drive the pathogenesis of acute lymphoblastic leukemia (ALL) and related disorders and then using this information to develop experimental models that faithfully recapitulate the genetics of human ALL to gain mechanistic insights and advances in diagnosis and therapy.

John E. Dick, PhD, FRS is a Senior Scientist at the Princess Margaret Cancer Centre and Affiliate Faculty Member, McEwen Stem Cell Institute, University Health Network. He also serves as Professor of Molecular Genetics at the University of Toronto and is Co-Leader for the Acute Leukemia-Translational Research Initiative, Ontario Institute for Cancer Research, Toronto. His research enabled isolation and characterization of normal and leukemic human hematopoietic stem cells and progenitors at single-cell resolution, and provided direct evidence for the cancer stem cell hypothesis. His work is currently aimed at elucidating the origin and nature of cancer and development of new approaches to cancer therapy.

 


Publications Division
American Association for Cancer Research
615 Chestnut Street  |  17th Floor  |  Philadelphia, PA 19106-4404
Phone: (215) 440-9300  |  Fax: (215) 440-9354  |  E-mail:  pubs@aacr.org

  • Home
  • Alerts
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Article Collections

  • Focus Selections
  • "Best of" Collection

Info for:

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

AACR Journals

  • About AACR Journals
  • 3rd Party Permissions & Reprints
AACR logo

Copyright © 2021 by the American Association for Cancer Research.